FDA Approves Orzeyful (oveporexton) for Narcolepsy Type 1

The U.S. Food and Drug Administration (FDA) has approved Orzeyful (oveporexton) for the treatment of narcolepsy type 1 in adults. This marks the first drug of its kind to address the underlying biology of the disease by directly activating the brain receptor that the body's own orexin would normally stimulate, thereby restoring the missing signal. The approval aims to provide a comprehensive treatment for the range of symptoms associated with narcolepsy type 1, including excessive daytime sleepiness, cataplexy, sleep paralysis, and hallucinations.